The syngo Virtual Cockpit platform reportedly enables remote access and image acquisition for CT, MRI and positron emission tomography (PET), and facilitates clinician collaboration across multiple sites.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the syngo Virtual Cockpit, a multi-vendor remote scanning platform that may help facilitate improved access to advanced imaging for patients in remote locations.
The syngo Virtual Cockpit enables remote access for computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and single-photon emission CT (SPECT) imaging, according to Siemens Healthineers, the manufacturer of the software. The company said the remote platform also features live video and chat functionalities to foster collaboration between clinicians across multiple sites.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the syngo Virtual Cockpit, a multi-vendor remote scanning platform that may enable access to MRI, CT and positron emission tomography (PET) imaging for patients in remote locations.
In addition to possibly facilitating improved standardization for imaging of remote patients, Siemens Healthineers suggested the syngo Virtual Cockpit could be utilized in training staff at remote facilities.
“This FDA clearance means that our customers can use syngo Virtual Cockpit for their remote scanning operations with even more confidence that they are using a proven solution — one that prioritizes patient safety and convenience while also addressing operational and staffing challenges,” noted Peter Shen, head of digital and automation at Siemens Healthineers North America.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.